Eloxatin

(Oxaliplatin)

ApprovedSmall molecule

Oxaliplatin is a chemotherapy drug used to treat colorectal cancer and other cancers by damaging cancer cell DNA to stop them from growing and dividing.[2] Eloxatin is currently approved and in use across 121 indications[4].[1]

Eloxatin is one of 1433 small molecule programs targeting Pancreatic Carcinoma. It is currently in Approved.

121

Indications

1,213

Total Trials

Active Trials

1,432

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Pancreatic CarcinomaActive, not recruiting

Pancreatic NeoplasmApproved

Peritoneum CancerApproved

Gastroesophageal Junction AdenocarcinomaActive, not recruiting

Colorectal CarcinomaActive, not recruiting

Non-Hodgkins LymphomaApproved

MetastasisActive, not recruiting

Esophageal Squamous Cell CarcinomaActive, not recruiting

Primitive Neuroectodermal TumorActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Pancreatic CarcinomaPhase 3

Active, not recruiting

Pancreatic NeoplasmApproved

Approved

Peritoneum CancerApproved

Approved

Gastroesophageal Junction AdenocarcinomaPhase 3

Active, not recruiting

Colorectal CarcinomaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

MetastasisPhase 2

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Primitive Neuroectodermal TumorPhase 2

Active, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Showing 10 of 121 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Approved

7 2

Tecentriq

Roche

Preclinical

36 3

Trodelvy

Gilead

Preclinical

37 4

Halaven

Eisai

Preclinical

38 5

Tykerb

GSK

Preclinical

80 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Metastatic Colorectal Cancer

NCT04854668

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT05731726

Phase 3Active, not recruiting

Liver Cancer

NCT03533582

Q1 2027

Phase 2Recruiting

Gastroesophageal Junction Cancer

NCT05476796

Phase 2Recruiting

Locally-Advanced Rectal Cancer

NCT06840665

Phase 2Recruiting

Colorectal Cancer

NCT06885385

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer27 trials

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04607421·831 enrolled

A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 3·NCT00069108·627 enrolled

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06733038·238 enrolled

Show 24 more trials

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Active, not recruiting·AAkeso·Phase 2·NCT05382442·254 enrolled

Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT01955629·4 enrolled

A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01490866·70 enrolled

Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00049101

Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193219·36 enrolled

Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer

Active, not recruiting·VVejle Hospital·Phase 2·NCT04245865·83 enrolled

Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer

Unknown status·—·Phase 1/2·NCT04008511·54 enrolled

Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01832948·30 enrolled

Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Unknown status·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT04262687·55 enrolled

Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Completed·PPrologue Research International·Phase 2·NCT00017082

Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

Completed·UUNICANCER·Phase 2·NCT00066274

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04854668·748 enrolled

Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Terminated·FFox Chase Cancer Center·N/A·NCT01280643·3 enrolled

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT01399684·127 enrolled

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01270438

First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib

Completed· Bayer logo

Bayer·Phase 2·NCT01289821·54 enrolled

Study of Pembrolizumab With Pemetrexed and Oxaliplatin in Chemo-Refractory Metastatic Colorectal Cancer Patients

Unknown status·NNSABP Foundation Inc·Phase 1·NCT03626922·33 enrolled

QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07025239·430 enrolled

Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer

Completed·MMedical Research Council·Phase 3·NCT00008060

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Recruiting·SShanghai Zhongshan Hospital·Phase 1·NCT06225622·78 enrolled

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT05253651·400 enrolled

A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

Terminated· Roche logo

Roche·Phase 2·NCT02141295·197 enrolled

MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer

Terminated·—·Phase 2·NCT00602329·5 enrolled

Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer

Completed· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Phase 1·NCT02848443·78 enrolled

Colorectal Cancer21 trials

FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01566942·200 enrolled

Combination Chemotherapy After Surgery in Treating Patients With High-Risk Stage II or Stage III Colorectal Cancer

Completed·CCancer Research UK, Glasgow·Phase 3·NCT00749450·6,088 enrolled

Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer

Completed· AbbVie logo

AbbVie·Phase 2·NCT00707889·159 enrolled

Show 18 more trials

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Unknown status·CCriterium, Inc.·Phase 2·NCT04169347·27 enrolled

Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06547385·40 enrolled

Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00070265·80 enrolled

Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00026234·75 enrolled

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Completed·HHuashan Hospital·Phase 3·NCT03365765·63 enrolled

Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT01529164·51 enrolled

A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06948448·144 enrolled

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery

Unknown status·—·Phase 2·NCT00513266·35 enrolled

Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00103298

Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan

Unknown status·YYonsei University·Phase 1/2·NCT00496704·56 enrolled

Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Completed·UUNICANCER·Phase 3·NCT00769405·264 enrolled

Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT02785146·230 enrolled

Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer

Completed·MMedical Research Council·Phase 2/3·NCT00975897·3,240 enrolled

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00215982·24 enrolled

Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 2/3·NCT06441565·84 enrolled

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT06885385·60 enrolled

Combination Chemotherapy in Treating Patients With Colorectal Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00039208

Biomarker-Guided Fluorouracil in Treating Patients With Colorectal Cancer Receiving Combination Chemotherapy

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01164215·76 enrolled

Gastric Cancer21 trials

Perioperative Chemotherapy in Gastric Cancer

Terminated·UUkrainian Society of Clinical Oncology·Phase 2·NCT04937738·69 enrolled

LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib

Completed· Novartis logo

Novartis·Phase 3·NCT00680901·545 enrolled

A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

Completed· Roche logo

Roche·Phase 2·NCT01130337·36 enrolled

Show 18 more trials

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 2·NCT06256328·226 enrolled

Sequential HIPEC of Oxaliplatin and Paclitaxel for Gastric Cancer Patients With Peritoneum Metastasis

Unknown status·PPeking University·Phase 2·NCT01471132·20 enrolled

Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients

Unknown status·JJinling Hospital, China·Phase 3·NCT02338518·297 enrolled

T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy

Unknown status·—·Phase 2·NCT02250209·40 enrolled

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Completed·KKrankenhaus Nordwest·Phase 2/3·NCT01216644·716 enrolled

Gastric Cancer Organoids in the Screening of Neoadjuvant Drugs

Unknown status·DDong Bing Zhao··NCT06196554·40 enrolled

Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

Recruiting·HHallym University Medical Center·Phase 3·NCT04787354·976 enrolled

To Observe the Efficacy and Safety by Comparing Chemotherapy(Docetaxel, Oxaliplatin Plus S1 ) Followed With Radical Resection Versus Chemotherapy Alone in Advanced Gastric Cancer With Single Non-curable Factor.

Unknown status·SShanghai Zhongshan Hospital··NCT03001726·228 enrolled

Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer

Unknown status·TTianshu Liu·Phase 2·NCT02623153·200 enrolled

Toripalimab Combined With Chemotherapy as Neoadjuvant Treatment of Gastric Cancer

Unknown status·AAiping Zhou·Phase 2·NCT04119622·30 enrolled

A Pilot Study of Neoadjuvant TACiE in Locally Advanced Gastric Cancer

Unknown status·SShanghai Zhongshan Hospital·Phase 1·NCT05396326·20 enrolled

Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers

Withdrawn·WWashington University School of Medicine·Phase 2·NCT02296671

Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer

Unknown status·SSun Yat-sen University·Phase 2·NCT04250948·108 enrolled

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

Terminated·NNational Cancer Centre, Singapore·Phase 1·NCT02720926·3 enrolled

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02625610·499 enrolled

Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05974059·20 enrolled

Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

Active, not recruiting·—·Phase 2·NCT03764553·320 enrolled

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not yet recruiting·—·Phase 2·NCT06881017·140 enrolled

Pancreatic Cancer13 trials

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03563144

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT03403101·65 enrolled

Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02620800·12 enrolled

Show 10 more trials

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04447092·77 enrolled

Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection

Unknown status·FFudan University·Phase 3·NCT02506842·300 enrolled

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Completed·SStanford University·Phase 3·NCT01926197·27 enrolled

Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT01121848·108 enrolled

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer

Unknown status·LLudwig-Maximilians - University of Munich·Phase 2·NCT01729481·150 enrolled

Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer

Unknown status·UUniversity of Ulm·Phase 2·NCT00690300·44 enrolled

Study of Gemcitabine and Oxaliplatin With Radiation Therapy in Patients With Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00456599·71 enrolled

CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer

Completed·WWake Forest University Health Sciences·Phase 1·NCT01835041·21 enrolled

Study of Bevacizumab in Combination With 5-FU, Oxaliplatin and External Beam Radiation Followed by Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer

Terminated·MMassachusetts General Hospital·Phase 1/2·NCT00307723·52 enrolled

Adenocarcinoma10 trials

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Unknown status·—·Phase 2·NCT04442984·326 enrolled

Prospective Study With FLOT in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Completed·KKrankenhaus Nordwest·Phase 2·NCT00849615·252 enrolled

Bevacizumab, Capecitabine, and Oxaliplatin in Treating Advanced Small Intestinal or Ampulla of Vater Adenocarcinoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01208103·30 enrolled

Show 7 more trials

XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach

Unknown status·HHarbin Medical University·Phase 2·NCT01798251·40 enrolled

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Withdrawn·PPeking University·Phase 2·NCT04863430

Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus

Active, not recruiting·UUniversity Hospital Schleswig-Holstein·Phase 3·NCT02509286·438 enrolled

A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)

Terminated· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT04675983·36 enrolled

Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03675737·1,579 enrolled

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Completed·CCancer Trials Ireland·Phase 3·NCT01726452·377 enrolled

S0304 Induct Chemo Then Chemo-RT in Pts w/Locally Advanced Adenocarcinoma of the Rectum

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00070434

62 more indications

Locally-advanced Rectal Cancer9 trials

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Recruiting·ZZhejiang University·Phase 2·NCT05731726·50 enrolled

A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in High-Risk Locally Advanced Rectal Cancer

Not yet recruiting·TTao Zhang·Phase 3·NCT07113275·435 enrolled

Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02921256·363 enrolled

Show 6 more trials

MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT06840665·46 enrolled

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Recruiting·FFudan University·Phase 2·NCT07150949·138 enrolled

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00081289·146 enrolled

Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer

Completed·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT02340949·180 enrolled

Modified SCRT Followed by Tislelizumab Plus CAPOX for Locally Advanced Rectal Cancer

Completed·FFujian Cancer Hospital·Phase 2·NCT06333769·38 enrolled

SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer

Recruiting·UUniversity of Miami·Phase 1·NCT05412082·25 enrolled

Chemotherapy5 trials

Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature

Not yet recruiting·JJohn Neoptolemos·Phase 3·NCT05314998·394 enrolled

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Completed·—·Phase 1·NCT02021422·13 enrolled

Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy

Completed·EEdward Kim·N/A·NCT02569723·6 enrolled

Show 2 more trials

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

Recruiting· Astellas logo

Astellas·Phase 1·NCT07024615·25 enrolled

Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）

Not yet recruiting·JJIN JING·Phase 2·NCT05794750·50 enrolled

Esophageal Adenocarcinoma5 trials

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Unknown status·—·Phase 2·NCT02037048·63 enrolled

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

Not yet recruiting·AAmerican Association for Cancer Research·Phase 2·NCT07290985·121 enrolled

MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma

Completed·UUNICANCER·Phase 2·NCT01443065·162 enrolled

Show 2 more trials

A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Completed· Jazz Pharmaceuticals logo

Jazz Pharmaceuticals·Phase 2·NCT03929666·74 enrolled

Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma

Completed· Sanofi logo

Sanofi·Phase 2·NCT00816543·41 enrolled

Esophageal Cancer4 trials

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03281369·214 enrolled

Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04522336·16 enrolled

Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

Terminated·RRoswell Park Cancer Institute·Phase 1/2·NCT00093652

Show 1 more trial

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01928290·67 enrolled

Rectal Cancer4 trials

A Single Arm Trial of Oxaliplatin and 5FU With Concurrent Radiation in Patients With Metastatic Rectal Cancer

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00422864·26 enrolled

Oxaliplatin in Rectal Cancer

Terminated· Sanofi logo

Sanofi·Phase 1/2·NCT00259363·46 enrolled

Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer

Completed·VVirginia Commonwealth University·Phase 1·NCT02270606·14 enrolled

Show 1 more trial

Nodes-sparing Short-course Radiation Combined With CAPOX and Tislelizumab for MSS Middle and Low Rectal Cancer

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT05972655·32 enrolled

Bevacizumab3 trials

CAPOXIRI+Bevacizumab vs. FOLFOXIRI+Bevacizumab for mCRC

Unknown status· Roche logo

Roche·Phase 2·NCT04097444·112 enrolled

Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients

Recruiting·SSun Yat-sen University·Phase 2/3·NCT06280495·156 enrolled

Lohp, 5-Fu/Lv and Bevacizumab, Alternative With Cpt-11, 5-Fu/Lv and Cetuximab In Metastatic Crc

Terminated·—·Phase 2·NCT00755118·24 enrolled

Liver Metastases3 trials

Intrahepatic Chemotherapy to Patients With Non-resectable Liver Metastases From Solid Tumor

Unknown status·—·Phase 2·NCT01511146·100 enrolled

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05774964·100 enrolled

Treatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.

Unknown status·RRabin Medical Center·Phase 2·NCT04003792·49 enrolled

Diffuse Large B-Cell Lymphoma3 trials

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Completed·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT02692248·64 enrolled

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03321643·24 enrolled

Capecitabine3 trials

Effects of S-1 and Capecitabine on Coronary Artery Blood Flow

Terminated·HHeikki Joensuu·Phase 2·NCT02216149·20 enrolled

Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor

Completed·—·Phase 1·NCT00005839

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

Terminated·FFox Chase Cancer Center·Phase 2·NCT00321100·23 enrolled

Lymphoma3 trials

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Completed·WWashington University School of Medicine·Phase 1·NCT02181218·24 enrolled

Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Completed· Gilead logo

Gilead·Phase 1/2·NCT02348216·307 enrolled

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02953509·178 enrolled

Hepatocellular Carcinoma3 trials

Sorafenib + mFOLFOX for Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01775501·40 enrolled

Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma

Unknown status·CChinese Academy of Medical Sciences·Phase 1·NCT02403544·30 enrolled

Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed·TThe University of Hong Kong·Phase 2·NCT02716766·46 enrolled

Radiation Therapy2 trials

Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03300544·3 enrolled

Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery

Terminated·UUNICANCER·Phase 2·NCT00541112·19 enrolled

Advanced Biliary Tract Carcinoma2 trials

Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03111732·11 enrolled

Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma

Unknown status·SSamsung Medical Center·Phase 3·NCT01470443·240 enrolled

Advanced Solid Tumors2 trials

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Completed· BeiGene logo

BeiGene·Phase 1·NCT04047862·446 enrolled

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT06544655·213 enrolled

Pancreatic Adenocarcinoma2 trials

Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma

Completed·NNational Taiwan University Hospital·Phase 1/2·NCT00154791·45 enrolled

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00075452

First-line Treatment2 trials

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT05640726·30 enrolled

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07117435·7 enrolled

Total Neoadjuvant Therapy2 trials

Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer

Not yet recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06872606·33 enrolled

Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study

Not yet recruiting·FFudan University·Phase 2·NCT06390982·46 enrolled

Solid Tumors2 trials

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00091182·180 enrolled

Oxaliplatin for Children With Solid Tumors

Unknown status·SSidnei Epelman·Phase 2·NCT01558453·20 enrolled

Non-Small Cell Lung Cancer2 trials

Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Completed· Sanofi logo

Sanofi·Phase 2·NCT00356122·53 enrolled

Paclitaxel and Oxaliplatin in Treating Patients With Recurrent or Advanced Non-small Cell Lung Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00004126·38 enrolled

Locally Advanced Colon Cancer2 trials

Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer

Active, not recruiting·VVejle Hospital·Phase 3·NCT01918527·250 enrolled

Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06790212·168 enrolled

Pembrolizumab2 trials

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Recruiting· Astellas logo

Astellas·Phase 1/2·NCT05083481·366 enrolled

Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06576037·128 enrolled

Gastroesophageal Junction Cancer2 trials

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT01498289·213 enrolled

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting·UUNICANCER·Phase 2·NCT05476796·118 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·BBeijing Biostar Pharmaceuticals Co., Ltd.·Phase 2/3·NCT06841679·778 enrolled

Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting·AAkeso·Phase 2·NCT05960955·90 enrolled

DLBCL1 trial

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Recruiting·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT07451652·10 enrolled

Advanced Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00043121·50 enrolled

Cervical Cancer1 trial

Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00057863·35 enrolled

Immunotherapy1 trial

The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer

Recruiting·FFudan University·Phase 2·NCT05555888·34 enrolled

Peritoneal Metastases1 trial

Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers

Terminated·IInstitut Cancerologie de l'Ouest·Phase 1/2·NCT03294252·34 enrolled

Hepatocellular Cancer1 trial

A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer

Terminated·—·Phase 2·NCT03026803·4 enrolled

Colorectal Carcinoma1 trial

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma

Unknown status·—·Phase 2·NCT04668976·100 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Breast Cancer1 trial

Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer

Terminated·HHoosier Cancer Research Network·Phase 2·NCT00216073·11 enrolled

Efficacy1 trial

A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)

Recruiting·BBelgian Group of Digestive Oncology·Phase 2·NCT05472259·134 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

Leukemia1 trial

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00472849·92 enrolled

Gastroesophageal Junction1 trial

Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00938470·73 enrolled

Esophagus Cancer1 trial

Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer

Completed·KKrankenhaus Nordwest·Phase 2·NCT00737373·143 enrolled

Colon Cancer1 trial

Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery

Unknown status·UUniversity of Birmingham·Phase 2/3·NCT00647530·1,053 enrolled

Advanced or Metastatic Solid Tumors1 trial

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Recruiting· Pfizer logo

Pfizer·Phase 1·NCT07318805·260 enrolled

Advanced Cancers1 trial

Oxaliplatin to Treat Advanced Cancers With Liver Dysfunction

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00006062·60 enrolled

Neoadjuvant Chemotherapy1 trial

Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC

Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1/2·NCT07365592·138 enrolled

Biliary Tract Cancer1 trial

Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers

Completed·TThe Christie NHS Foundation Trust·Phase 3·NCT01926236·162 enrolled

Intestinal Cancer1 trial

Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003427·36 enrolled

Gastric Carcinoma1 trial

PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Completed·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT03006432·507 enrolled

Rectal Adenocarcinoma1 trial

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

Recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06266832·30 enrolled

Stomach Cancer1 trial

Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00411229·1,035 enrolled

Metastases1 trial

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Completed·UUNICANCER·Phase 2·NCT01442935·256 enrolled

Biliary Cancer1 trial

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

Withdrawn·UUniversity Health Network, Toronto·Phase 1·NCT02105350

Chemoradiation1 trial

Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

Completed·—·Phase 2·NCT00831181·27 enrolled

Primary Peritoneal Cancer1 trial

Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy

Completed·GGynecologic Oncology Group·Phase 2·NCT00005836

Relapsed or Refractory1 trial

Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01039155·41 enrolled

Radiotherapy1 trial

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Recruiting·—·Phase 2·NCT07165847·40 enrolled

Unresectable Colorectal Liver Metastases1 trial

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Recruiting·EECOG-ACRIN Cancer Research Group·Phase 3·NCT05863195·408 enrolled

Small Cell Lung Cancer1 trial

Gemcitabine Plus Oxaliplatin in Advanced Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Unknown status·NNational Cancer Center, Korea·Phase 2·NCT00453115·43 enrolled

Nasopharyngeal Carcinoma1 trial

Combination of Capecitabine and Oxaliplatin in Metastatic Nasopharyngeal Carcinoma

Unknown status·TThe University of Hong Kong·Phase 2·NCT00363831·42 enrolled

Tislelizumab1 trial

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05319639·51 enrolled

Liver Cancer1 trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT03533582·537 enrolled

CRC1 trial

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03493048·146 enrolled

Neurotoxicity1 trial

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Completed· Sanofi logo

Sanofi·Phase 3·NCT00305188·879 enrolled

Ivonescimab1 trial

Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07070466·40 enrolled

Head and Neck Cancer1 trial

Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256308·6 enrolled

Germ Cell Tumor1 trial

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Completed·UUNICANCER·Phase 3·NCT00104676·263 enrolled

Regulatory

FDA Approval Timeline[5]

Aug 9, 2002

ELOXATIN

NDA NDA021492

Jan 31, 2005

ELOXATIN

NDA NDA021759

Aug 7, 2009

OXALIPLATIN

NDA NDA022160

Sources

References

[1]
ClinicalTrials.gov — 1213 trial records for Oxaliplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Eloxatin drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Oxaliplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Oxaliplatin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA022160). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Eloxatin

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Trials by Indication[1]

Metastatic Colorectal Cancer27 trials

Colorectal Cancer21 trials

Gastric Cancer21 trials

Pancreatic Cancer13 trials

Adenocarcinoma10 trials

Locally-advanced Rectal Cancer9 trials

Chemotherapy5 trials

Esophageal Adenocarcinoma5 trials

Esophageal Cancer4 trials

Rectal Cancer4 trials

Bevacizumab3 trials

Liver Metastases3 trials

Diffuse Large B-Cell Lymphoma3 trials

Capecitabine3 trials

Lymphoma3 trials

Hepatocellular Carcinoma3 trials

Radiation Therapy2 trials

Advanced Biliary Tract Carcinoma2 trials

Advanced Solid Tumors2 trials

Pancreatic Adenocarcinoma2 trials

First-line Treatment2 trials

Total Neoadjuvant Therapy2 trials

Solid Tumors2 trials

Non-Small Cell Lung Cancer2 trials

Locally Advanced Colon Cancer2 trials

Pembrolizumab2 trials

Gastroesophageal Junction Cancer2 trials

Gastroesophageal Junction Adenocarcinoma2 trials

DLBCL1 trial

Advanced Cancer1 trial

Cervical Cancer1 trial

Immunotherapy1 trial

Peritoneal Metastases1 trial

Hepatocellular Cancer1 trial

Colorectal Carcinoma1 trial

Advanced Malignant Solid Tumors1 trial

Breast Cancer1 trial

Efficacy1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Leukemia1 trial

Gastroesophageal Junction1 trial

Esophagus Cancer1 trial

Colon Cancer1 trial

Advanced or Metastatic Solid Tumors1 trial

Advanced Cancers1 trial

Neoadjuvant Chemotherapy1 trial

Biliary Tract Cancer1 trial

Intestinal Cancer1 trial

Gastric Carcinoma1 trial

Rectal Adenocarcinoma1 trial

Stomach Cancer1 trial

Metastases1 trial

Biliary Cancer1 trial

Chemoradiation1 trial

Primary Peritoneal Cancer1 trial

Relapsed or Refractory1 trial

Radiotherapy1 trial

Unresectable Colorectal Liver Metastases1 trial

Small Cell Lung Cancer1 trial

Nasopharyngeal Carcinoma1 trial

Tislelizumab1 trial

Liver Cancer1 trial

CRC1 trial

Neurotoxicity1 trial

Ivonescimab1 trial

Head and Neck Cancer1 trial

Germ Cell Tumor1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News